40
Participants
Start Date
June 30, 2014
Primary Completion Date
July 31, 2017
Study Completion Date
July 31, 2017
PF-06650808
Dose Escalation Phase \[Part 1\] - PF-06650808 will be administered at doses starting at 0.2 mg/kg. Increases in dose will continue until MTD is determined.
PF-06650808
Dose Expansion Phase \[Part 2\] - Patients will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
The Ohio State University James Cancer Hospital, Columbus
The OSU Investigational Drug Services, Columbus
The OSU Stephanie Spielman Comprehensive Breast Center, Columbus
The Ohio State University Martha Morehouse Medical Plaza, Columbus
South Texas Accelerated Research Therapeutics, LLC (START), San Antonio
Ronald Reagan UCLA Medical Center, Drug Information Center, Los Angeles
Ronald Reagan UCLA Medical Center, Los Angeles
UCLA Hematology/Oncology, Los Angeles
Westwood Bowyer Clinic, Los Angeles
Santa Monica - UCLA Medical Center & Orthopaedic Hospital, Santa Monica
UCLA Hematology/Oncology - Santa Monica, Santa Monica
Lead Sponsor
Pfizer
INDUSTRY